Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients

NCT02596334 is registered in ClinicalTrials.gov with Centre Hospitalier Régional d'Orléans as lead sponsor.

NCT NCT02596334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02596334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients
Lead sponsor
Centre Hospitalier Régional d'Orléans
Phase
Phase 3
Overall status
Terminated
Start date
December 23, 2015
Completion date
June 23, 2018
Enrollment
158 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv